Adcendo
A spin-out from The University of Copenhagen and Rigshospitalet, Adcendo is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (ADCs). The company's drugs are directed at a target receptor uPARAP, which allows targeted therapy in several cancer forms where expression of the target has been found to be highly unregulated, including soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme (GBM) and triple-negative breast cancer. This, in turn, enables doctors to treat patients with diseases including carcinomas, including breast, colon, pancreatic, prostate, ovarian and renal cancers.
Founded 2017
Employees 25+
Funding 💰
Total $97.3M
Select investors Novo Holdings, Ysios Capital, RA Capital Management, HealthCap, Gilde Healthcare, Pontifax
Key people 🧑🤝🧑
- Michael Pehl, MSc - CEO
- Dominik Mumberg, PhD - CSO
- Carmel M. Lynch, PhD - CDO
- Pernille Hemmingsen, PhD - CTO
- Christoffer Nielsen, PhD - Co-founder & COO
- James Wang - Head of Business Development
- Lasse René Sørensen - Finance Director
- Karen Bannister - Executive Director Program Management
- Niels Behrendt, PhD, DSc - Scientific Co-Founder
- Lars H. Engelholm, PhD - Scientific Co-Founder
Highlights ⭐
- Treating underserved cancers: The company is focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, such as soft tissue sarcoma, osteosarcoma, mesothelioma, and glioblastoma.
- Proof of concept data: Adcendo has generated in-vivo proof of concept data with its lead uPARAP ADC asset in multiple target indications and with multiple payload MoAs. 🔗
- Experienced CEO: In July 2021, Adcendo appointed Michael Pehl as Chief Executive Officer. He has over 25 years of international biotechnology and oncology leadership experience in both the US and Europe. Michael joined Adcendo from GEMoaB, where he served as CEO and led the formation and launch of a globally leading allogeneic CAR-T company together with Blackstone Life Sciences and Intellia Therapeutics. Prior to this, he was CEO of Immunomedics, leading the development of sacituzumab govitecan in metastatic triple-negative breast cancer, which was approved in the U.S. in 2020. Immunomedics was acquired by Gilead in 2020 for $21 billion.
Awards & Recognitions 🏆
- 2022 World ADC Awards: Best New Drug Developer shortlist 🔗
Quotes 💬
“
Novo Seeds is focused on building world class companies that are developing innovative treatments for patients with unmet medical needs. We are proud to have been involved with the company since its early days and are very impressed with the progress achieved to date. We are very pleased to now co-lead this strong investment, building on the founders' early-stage research at The Finsen Laboratory to develop Adcendo into a world leading ADC player with a pipeline of exciting novel ADC drugs.
— Jeroen Bakker, Principal at Novo Seeds 🔗
“
Adcendo is taking the ADC approach to the next level by focusing on targets that are professional internalizers and have exquisite tumor selectivity. We are very pleased to support this financing.
— Joël Jean-Mairet, Managing Partner at Ysios Capital 🔗
“
We are excited to support Adcendo's efforts to bring new treatments to patients with cancer as we continue our focus on seeking exciting transformative technologies to treat substantial unmet medical need indications. Adcendo's ADC capabilities offer significant potential and I look forward to closely working with the team to develop their pipeline assets and bring innovative therapies to patients in need.
— Ohad Hammer, Board Director of Adcendo and Partner at Pontifax Venture Capital 🔗
Last update: June 4, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more